RT Journal Article
SR Electronic
T1 SARS-CoV-2 Antibody Response in Patients Undergoing Kidney Transplantation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.25.21261066
DO 10.1101/2021.07.25.21261066
A1 Lubetzky, Michelle
A1 Sukhu, Ashley
A1 Zhao, Zhen
A1 Rand, Sophie
A1 Sharma, Vijay
A1 Sultan, Samuel
A1 Kapur, Zoe
A1 Albakry, Shady
A1 Hauser, Nataliya
A1 Marku-Podvorica, Jehona
A1 Craig-Schapiro, Rebecca
A1 Lee, John R.
A1 Salinas, Thalia
A1 Aull, Meredith
A1 Kapur, Sandip
A1 Cushing, Melissa
A1 Dadhania, Darshana M.
YR 2021
UL http://medrxiv.org/content/early/2021/07/28/2021.07.25.21261066.abstract
AB The response of the immune system to COVID-19 in end stage kidney disease patients who undergo kidney transplantation has yet to be described. We report data on 72 patients who underwent SARS-CoV-2 antibody testing both before and after kidney transplantation and were followed for a median of 186 days (range 83, 277). Of the 25 patients with a positive antibody test at the time of transplant, 17 (68%) remained positive after transplantation. Patients were significantly more likely to have a persistently positive test if they reported a symptomatic COVID-19 infection prior to transplant (p=0.01). SARS-CoV-2 IgG index values were measured in a subset of kidney transplant recipients and compared to wait -listed dialysis patients. These assays demonstrated a more significant decline in IgG (58% versus 14% p = 0.008) in transplant recipients when compared to dialysis patients tested during the same time period. Additional analysis of the quality of the immune response measuring the binding of SARS-CoV-2 antibodies to the receptor-binding domain (RBD binding), the antibody neutralizing capability, and the antibody avidity demonstrated a more pronounced effect when comparing pre-transplant values to post-induction therapy/post transplant values. The attenuated IgG response seen in transplant patients compared to dialysis patients after induction therapy requires further study. These data have important implications for post-transplant management of vaccinated dialysis patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors did not receive funding for the submitted workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Weill Cornell Medicine Institutional Review Board protocol # 1207012637 entitled Utilizing a Transplant Database for Quality Assessment and Performance Improvement and Clinical Outcomes and protocol # 20-05022154 entitled Impact of COVID-19 Illness on Kidney Transplant Candidates and Recipients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data is available upon request